Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SyB L-0501 + Rituximab in R/R DLBCL
NCT01118845Phase 2Completed
- Sponsor
- SymBio Pharmaceuticals
- Start
- Apr 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of bendamustine in diffuse large B-cell lymphoma (DLBCL), sponsored by SymBio Pharmaceuticals. Primary endpoint: Overall Response Rate at 30 weeks. Started Apr 2010; status: completed.
02
Drugs
bendamustine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01118845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01118845.